Tag: Angioedema Treatment Market Share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Angioedema Treatment Market Growth Potential: How Will Market Size Shift Through 2030?

The angioedema treatment market has seen rapid expansion in recent years. Its valuation is set to rise from $3.13 billion in 2025 to $3.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this market’s growth can be attributed to elements like emergency allergy management, hospital-based care, the utilization of corticosteroids, the presence of antihistamine options, and the limited availability of highly targeted medications.

The angioedema treatment market is anticipated to experience significant expansion over the coming years, reaching $6.18 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. This projected increase during the forecast period is largely due to advancements in biologic drug development, the rise in genetic testing, the establishment of specialized allergy clinics, enhanced patient education, and a greater emphasis on preventive care. Key developments expected during this period involve a rise in targeted bradykinin therapies, an increase in hereditary angioedema treatments, the broader implementation of emergency treatment protocols, improved understanding of diagnostics, and a focus on proactive therapeutic strategies.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Angioedema Treatment Market Growth Catalysts And Demand Drivers

The angioedema treatment market is anticipated to expand moving forward due to an uptick in the occurrence of rare diseases. Rare diseases are defined as medical conditions that affect a very small segment of the population, often presenting with limited therapeutic options and considerable health consequences. The increasing prevalence of rare diseases is attributed to breakthroughs in genetic testing and diagnostic technologies, enabling healthcare professionals to detect and accurately diagnose conditions previously overlooked, thereby leading to a higher reported frequency. Angioedema treatment proves beneficial for rare diseases like hereditary angioedema by delivering targeted therapies that assist in preventing and managing severe swelling episodes, thus improving patient outcomes. For instance, in November 2024, the Food and Drug Administration, a US-based federal agency, reported that over 7,000 rare diseases impacted more than 30 million individuals in the United States. Therefore, the growing incidence of rare diseases is fueling the expansion of the angioedema treatment market.

Angioedema Treatment Market Breakdown By Product Type And Application

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Angioedema Treatment Market Trends Shaping Long-Term Demand

Leading companies in the angioedema treatment market are concentrating on developing innovative therapies, such as subcutaneous injections, to provide patients suffering from acute hereditary angioedema (HAE) attacks with more convenient and rapid relief. Subcutaneous injections involve administering medication into the fatty tissue just beneath the skin for slow and steady absorption into the bloodstream. As an illustration, in April 2025, CSL Limited, an Australia-based biotechnology company, launched ANDEMBRY (garadacimab), a novel, fully human monoclonal antibody treatment aimed at preventing acute attacks in individuals with hereditary angioedema (HAE). ANDEMBRY stands as the first pre-filled pen designed for once-monthly subcutaneous administration, offering a convenient long-term prophylactic alternative. This drug functions by inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the cascade that leads to angioedema. It signifies a substantial advancement in HAE management by delivering effective, patient-centric disease control.

Angioedema Treatment Market Company Landscape And Competitive Strategy

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

View The Full Angioedema Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Angioedema Treatment Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Angioedema Treatment Market Expansion From $3.59 Billion In 2026 To $6.18 Billion In 2030

In recent years, the angioedema treatment market has experienced swift expansion, climbing from $3.13 billion in 2025 to $3.59 billion in 2026, reflecting a robust compound annual growth rate (CAGR) of 14.8%. Historical growth was driven by factors such as emergency allergy management, hospital-based care, corticosteroid usage, the availability of antihistamines, and a limited arsenal of targeted therapies.

The angioedema treatment market is projected to experience significant expansion in the coming years, reaching an estimated value of $6.18 billion by 2030, with a compound annual growth rate (CAGR) of 14.5%. This anticipated growth during the forecast period is driven by factors such as the development of biologic drugs, the rise of genetic testing, the establishment of specialized allergy clinics, enhanced patient education, and a stronger emphasis on preventive care. Key trends shaping this period include the growing adoption of targeted bradykinin therapies, the advancement of treatments for hereditary angioedema, the broadening of emergency treatment protocols, heightened diagnostic awareness, and a concentrated effort on preventive therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Angioedema Treatment Market Growth Drivers: What Factors Are Accelerating Expansion?

A growing prevalence of rare diseases is anticipated to drive expansion in the angioedema treatment market moving forward. These rare diseases are health conditions affecting only a tiny fraction of the population, frequently characterized by scarce therapeutic options and substantial health consequences. Their increasing occurrence stems from progress in genetic testing and diagnostic tools, which allow medical professionals to identify and accurately diagnose conditions that were previously overlooked, thereby raising the reported rate of prevalence. Angioedema treatments play a beneficial role in conditions like hereditary angioedema by offering targeted therapies for preventing and controlling severe swelling episodes, thus enhancing patient outcomes. As an example, the Food and Drug Administration, a U.S. federal agency, reported in November 2024 that over 7,000 rare diseases affected more than 30 million people in the United States. Consequently, the rising incidence of rare diseases is fueling growth in the angioedema treatment market.

Angioedema Treatment Market Segment Landscape And Growth Potential

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Angioedema Treatment Market Trends: What Is Shaping Future Industry Growth?

Leading players in the angioedema treatment market are actively developing innovative approaches, specifically subcutaneous injections, designed to deliver faster and more convenient relief for individuals with acute hereditary angioedema (HAE) attacks. This delivery technique involves administering medication directly into the fatty layer beneath the skin, facilitating gradual and consistent absorption into the bloodstream. A notable example occurred in April 2025, when CSL Limited, a biotechnology firm based in Australia, introduced ANDEMBRY (garadacimab)—a novel, fully human monoclonal antibody aimed at preventing acute episodes in hereditary angioedema (HAE) patients. As the first pre-filled pen for once-monthly subcutaneous use, ANDEMBRY provides a practical option for long-term prophylaxis. Its mechanism of action involves blocking activated Factor XII (Factor XIIa), a crucial trigger in the cascade that initiates angioedema. This development marks a substantial step forward in HAE management, offering effective, patient-focused disease control.

Angioedema Treatment Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Access The Complete Angioedema Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Angioedema Treatment Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Angioedema Treatment Market?

The angioedema treatment market has shown significant growth in its size over recent years. It is forecast to rise from $3.13 billion in 2025 to $3.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.8%. The expansion during the preceding period is attributable to elements like emergency allergy management, hospital-based care, the application of corticosteroids, the accessibility of antihistamines, and the constrained number of targeted drugs.

The angioedema treatment market is projected to experience substantial expansion in the coming years, reaching $6.18 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. This anticipated growth is driven by factors such as advancements in biologic drug development, the expansion of genetic testing, the establishment of specialized allergy clinics, enhanced patient education, and a heightened emphasis on preventive care. Key developments during this period will involve a rise in the application of targeted bradykinin therapies, an increase in hereditary angioedema treatments, the broadening of emergency treatment guidelines, greater diagnostic understanding, and a focus on preventative interventions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

Which Major Factors Are Contributing To The Development Of The Angioedema Treatment Market?

A growing prevalence of rare diseases is projected to stimulate the expansion of the angioedema treatment market moving forward. These medical conditions impact a minimal segment of the population, frequently presenting with restricted therapeutic options and considerable health consequences. The heightened occurrence of rare diseases is attributed to breakthroughs in genetic testing and diagnostic technologies, which empower healthcare providers to identify and precisely diagnose conditions that were previously undetected, thus contributing to an elevated reported prevalence. Angioedema treatment offers benefits for rare ailments like hereditary angioedema through focused treatments that assist in preventing and controlling severe swelling episodes, thereby enhancing patient results. For example, in November 2024, the Food and Drug Administration, a US-based federal agency, reported that over 7,000 rare diseases affected more than 30 million individuals in the United States. Consequently, the increasing incidence of rare diseases is fueling the growth of the angioedema treatment market.

How Is The Angioedema Treatment Market Examined Through Segment Analysis?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Which Trends Are Influencing The Expansion Of The Angioedema Treatment Market?

Leading companies in the angioedema treatment market are concentrating on developing innovative solutions, such as subcutaneous injections, to provide more convenient and rapid relief for patients experiencing acute hereditary angioedema (HAE) attacks. Subcutaneous injections involve administering medication into the fatty tissue just beneath the skin for its slow and steady absorption into the bloodstream. As an illustration, in April 2025, CSL Limited, an Australia-based biotechnology company, introduced ANDEMBRY (garadacimab). This product is a novel, fully human monoclonal antibody treatment aimed at preventing acute attacks in patients with hereditary angioedema (HAE). ANDEMBRY represents the first pre-filled pen for once-monthly subcutaneous administration, offering a convenient long-term prophylactic option. The drug functions by inhibiting activated Factor XII (Factor XIIa), which is a key initiator in the cascade that leads to angioedema. This marks a significant advancement in HAE management by delivering effective, patient-centric disease control.

Who Are The Major Companies Operating In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Access The Complete Angioedema Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Region Leads The Angioedema Treatment Market By Size?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Angioedema Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Angioedema Treatment Market Grow Between 2026 And 2030?

The angioedema treatment market has observed substantial growth in recent years. Its value is expected to rise from $3.13 billion in 2025 to $3.59 billion in 2026, representing a compound annual growth rate (CAGR) of 14.8%. This historical growth can be linked to factors like emergency allergy management, hospital-based care, the application of corticosteroids, the widespread availability of antihistamines, and the restricted number of targeted medications.

The angioedema treatment market is projected to experience substantial expansion over the upcoming years. This market is set to reach a value of $6.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. Factors contributing to this growth during the forecast period include advancements in biologic drug development, the increase in genetic testing, the proliferation of specialty allergy clinics, enhanced patient education, and a greater emphasis on preventive care. Key trends anticipated for the forecast period encompass a rising adoption of targeted bradykinin therapies, the expansion of hereditary angioedema treatment options, broadened emergency treatment protocols, heightened diagnostic awareness, and a strategic focus on preventive therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

What Key Drivers Are Fueling The Growth Of The Angioedema Treatment Market?

The angioedema treatment market is projected to experience growth due to an increasing occurrence of rare diseases. Rare diseases are characterized as medical conditions affecting a small segment of the population, often accompanied by limited therapeutic options and significant health implications. The prevalence of rare diseases is on the rise, primarily attributed to advancements in genetic testing and diagnostic technologies. These developments enable healthcare professionals to detect and accurately diagnose conditions that were previously overlooked, leading to a higher reported incidence. Angioedema treatment proves beneficial for rare diseases, including hereditary angioedema, by providing targeted therapies that aid in preventing and managing severe swelling episodes, thus improving patient outcomes. For instance, in November 2024, the Food and Drug Administration, a US-based federal agency, indicated that more than 7,000 rare diseases impacted over 30 million individuals in the United States. Therefore, the increasing incidence of rare diseases is a key factor driving the expansion of the angioedema treatment market.

How Is The Angioedema Treatment Market Organized By Segment Classification?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

What Market Trends Are Affecting The Angioedema Treatment Market?

Companies operating in the angioedema treatment market are concentrating on creating innovative solutions, including subcutaneous injections, to provide more convenient and swift relief for patients suffering from acute hereditary angioedema (HAE) attacks. Subcutaneous injections represent a method of delivering medication into the fatty tissue directly beneath the skin, allowing for slow and steady absorption into the bloodstream. As an example of this innovation, CSL Limited, an Australia-based biotechnology company, introduced ANDEMBRY (garadacimab) in April 2025. This novel, fully human monoclonal antibody treatment is intended for the prevention of acute attacks in individuals with hereditary angioedema (HAE). ANDEMBRY stands out as the first pre-filled pen designed for once-monthly subcutaneous administration, offering a practical long-term prophylactic choice. The drug functions by inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the cascade that leads to angioedema. Its introduction marks a significant step forward in HAE management, delivering effective and patient-focused disease control.

Who Are The Industry Participants Involved In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Get The Full Angioedema Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Geographic Region Dominates The Angioedema Treatment Market?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Angioedema Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Angioedema Treatment Market Grow Between 2026 And 2030?

The angioedema treatment market has observed substantial growth in recent years. Its value is expected to rise from $3.13 billion in 2025 to $3.59 billion in 2026, representing a compound annual growth rate (CAGR) of 14.8%. This historical growth can be linked to factors like emergency allergy management, hospital-based care, the application of corticosteroids, the widespread availability of antihistamines, and the restricted number of targeted medications.

The angioedema treatment market is projected to experience substantial expansion over the upcoming years. This market is set to reach a value of $6.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. Factors contributing to this growth during the forecast period include advancements in biologic drug development, the increase in genetic testing, the proliferation of specialty allergy clinics, enhanced patient education, and a greater emphasis on preventive care. Key trends anticipated for the forecast period encompass a rising adoption of targeted bradykinin therapies, the expansion of hereditary angioedema treatment options, broadened emergency treatment protocols, heightened diagnostic awareness, and a strategic focus on preventive therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

What Key Drivers Are Fueling The Growth Of The Angioedema Treatment Market?

The angioedema treatment market is projected to experience growth due to an increasing occurrence of rare diseases. Rare diseases are characterized as medical conditions affecting a small segment of the population, often accompanied by limited therapeutic options and significant health implications. The prevalence of rare diseases is on the rise, primarily attributed to advancements in genetic testing and diagnostic technologies. These developments enable healthcare professionals to detect and accurately diagnose conditions that were previously overlooked, leading to a higher reported incidence. Angioedema treatment proves beneficial for rare diseases, including hereditary angioedema, by providing targeted therapies that aid in preventing and managing severe swelling episodes, thus improving patient outcomes. For instance, in November 2024, the Food and Drug Administration, a US-based federal agency, indicated that more than 7,000 rare diseases impacted over 30 million individuals in the United States. Therefore, the increasing incidence of rare diseases is a key factor driving the expansion of the angioedema treatment market.

How Is The Angioedema Treatment Market Organized By Segment Classification?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

What Market Trends Are Affecting The Angioedema Treatment Market?

Companies operating in the angioedema treatment market are concentrating on creating innovative solutions, including subcutaneous injections, to provide more convenient and swift relief for patients suffering from acute hereditary angioedema (HAE) attacks. Subcutaneous injections represent a method of delivering medication into the fatty tissue directly beneath the skin, allowing for slow and steady absorption into the bloodstream. As an example of this innovation, CSL Limited, an Australia-based biotechnology company, introduced ANDEMBRY (garadacimab) in April 2025. This novel, fully human monoclonal antibody treatment is intended for the prevention of acute attacks in individuals with hereditary angioedema (HAE). ANDEMBRY stands out as the first pre-filled pen designed for once-monthly subcutaneous administration, offering a practical long-term prophylactic choice. The drug functions by inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the cascade that leads to angioedema. Its introduction marks a significant step forward in HAE management, delivering effective and patient-focused disease control.

Who Are The Industry Participants Involved In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Get The Full Angioedema Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Geographic Region Dominates The Angioedema Treatment Market?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Angioedema Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Angioedema Treatment Market From 2026 To 2030?

The angioedema treatment market has experienced rapid expansion in its size over recent years. Its valuation is projected to rise from $3.13 billion in 2025 to $3.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion can be linked to factors such as emergency allergy management, hospital-based care, the application of corticosteroids, the presence of antihistamines, and a scarcity of targeted drug options.

The angioedema treatment market size is projected to experience substantial growth over the next few years, with an anticipated increase to $6.18 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.5%. This growth in the forecast period is expected to be driven by advancements in biologic drug development, the expansion of genetic testing, the proliferation of specialty allergy clinics, improved patient education, and a heightened focus on preventive care. Significant trends for the forecast period include the increased utilization of targeted bradykinin therapies, the development of hereditary angioedema treatments, the broadening of emergency treatment protocols, enhanced diagnostic awareness, and a sustained emphasis on preventive therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

What Key Drivers Are Influencing The Growth Of The Angioedema Treatment Market?

The angioedema treatment market is projected to expand due to an increasing occurrence of rare diseases. These are health conditions impacting a small segment of the populace, frequently associated with few therapeutic choices and substantial health consequences. The heightened prevalence of rare diseases stems from innovations in genetic testing and diagnostic methods, which allow medical experts to identify and precisely diagnose conditions previously undiagnosed. Angioedema treatment plays a crucial role in managing rare diseases like hereditary angioedema, offering specific therapies to prevent and control acute swelling episodes, thereby enhancing patient results. For example, data from the US-based federal agency, the Food and Drug Administration, indicated that by November 2024, over 7,000 rare diseases affected more than 30 million individuals in the United States. Consequently, the growing frequency of rare diseases is a key factor propelling the expansion of the angioedema treatment market.

Which Segments Are Included In The Analysis Of The Angioedema Treatment Market?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Which Trends Are Impacting The Growth Of The Angioedema Treatment Market?

Leading companies within the angioedema treatment market are concentrating on creating advanced solutions, including subcutaneous injections, to provide patients experiencing acute hereditary angioedema (HAE) attacks with more convenient and quicker relief. Subcutaneous injections involve a technique where medication is administered into the fatty layer directly under the skin, facilitating its gradual and consistent absorption into the bloodstream. An illustrative example is CSL Limited, an Australia-based biotechnology company, which introduced ANDEMBRY (garadacimab) in April 2025. This product serves as a new, fully human monoclonal antibody therapy designed to prevent acute attacks in individuals with hereditary angioedema (HAE). Notably, ANDEMBRY stands as the inaugural pre-filled pen designed for once-monthly subcutaneous delivery, presenting an accessible long-term prophylactic alternative. Its mechanism involves inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the biochemical sequence that results in angioedema. This marks a substantial progression in HAE management, delivering effective, patient-focused disease control.

Which Key Industry Participants Are Active In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Read the full angioedema treatment market report here:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Angioedema Treatment Market?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Angioedema Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24460&type=smp

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Angioedema Treatment Market From 2026 To 2030?

The angioedema treatment market has experienced rapid expansion in its size over recent years. Its valuation is projected to rise from $3.13 billion in 2025 to $3.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion can be linked to factors such as emergency allergy management, hospital-based care, the application of corticosteroids, the presence of antihistamines, and a scarcity of targeted drug options.

The angioedema treatment market size is projected to experience substantial growth over the next few years, with an anticipated increase to $6.18 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.5%. This growth in the forecast period is expected to be driven by advancements in biologic drug development, the expansion of genetic testing, the proliferation of specialty allergy clinics, improved patient education, and a heightened focus on preventive care. Significant trends for the forecast period include the increased utilization of targeted bradykinin therapies, the development of hereditary angioedema treatments, the broadening of emergency treatment protocols, enhanced diagnostic awareness, and a sustained emphasis on preventive therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

What Key Drivers Are Influencing The Growth Of The Angioedema Treatment Market?

The angioedema treatment market is projected to expand due to an increasing occurrence of rare diseases. These are health conditions impacting a small segment of the populace, frequently associated with few therapeutic choices and substantial health consequences. The heightened prevalence of rare diseases stems from innovations in genetic testing and diagnostic methods, which allow medical experts to identify and precisely diagnose conditions previously undiagnosed. Angioedema treatment plays a crucial role in managing rare diseases like hereditary angioedema, offering specific therapies to prevent and control acute swelling episodes, thereby enhancing patient results. For example, data from the US-based federal agency, the Food and Drug Administration, indicated that by November 2024, over 7,000 rare diseases affected more than 30 million individuals in the United States. Consequently, the growing frequency of rare diseases is a key factor propelling the expansion of the angioedema treatment market.

Which Segments Are Included In The Analysis Of The Angioedema Treatment Market?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Which Trends Are Impacting The Growth Of The Angioedema Treatment Market?

Leading companies within the angioedema treatment market are concentrating on creating advanced solutions, including subcutaneous injections, to provide patients experiencing acute hereditary angioedema (HAE) attacks with more convenient and quicker relief. Subcutaneous injections involve a technique where medication is administered into the fatty layer directly under the skin, facilitating its gradual and consistent absorption into the bloodstream. An illustrative example is CSL Limited, an Australia-based biotechnology company, which introduced ANDEMBRY (garadacimab) in April 2025. This product serves as a new, fully human monoclonal antibody therapy designed to prevent acute attacks in individuals with hereditary angioedema (HAE). Notably, ANDEMBRY stands as the inaugural pre-filled pen designed for once-monthly subcutaneous delivery, presenting an accessible long-term prophylactic alternative. Its mechanism involves inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the biochemical sequence that results in angioedema. This marks a substantial progression in HAE management, delivering effective, patient-focused disease control.

Which Key Industry Participants Are Active In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Read the full angioedema treatment market report here:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Angioedema Treatment Market?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Angioedema Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24460&type=smp

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Angioedema Treatment Market From 2026 To 2030?

The angioedema treatment market has experienced rapid expansion in its size over recent years. Its valuation is projected to rise from $3.13 billion in 2025 to $3.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion can be linked to factors such as emergency allergy management, hospital-based care, the application of corticosteroids, the presence of antihistamines, and a scarcity of targeted drug options.

The angioedema treatment market size is projected to experience substantial growth over the next few years, with an anticipated increase to $6.18 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.5%. This growth in the forecast period is expected to be driven by advancements in biologic drug development, the expansion of genetic testing, the proliferation of specialty allergy clinics, improved patient education, and a heightened focus on preventive care. Significant trends for the forecast period include the increased utilization of targeted bradykinin therapies, the development of hereditary angioedema treatments, the broadening of emergency treatment protocols, enhanced diagnostic awareness, and a sustained emphasis on preventive therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

What Key Drivers Are Influencing The Growth Of The Angioedema Treatment Market?

The angioedema treatment market is projected to expand due to an increasing occurrence of rare diseases. These are health conditions impacting a small segment of the populace, frequently associated with few therapeutic choices and substantial health consequences. The heightened prevalence of rare diseases stems from innovations in genetic testing and diagnostic methods, which allow medical experts to identify and precisely diagnose conditions previously undiagnosed. Angioedema treatment plays a crucial role in managing rare diseases like hereditary angioedema, offering specific therapies to prevent and control acute swelling episodes, thereby enhancing patient results. For example, data from the US-based federal agency, the Food and Drug Administration, indicated that by November 2024, over 7,000 rare diseases affected more than 30 million individuals in the United States. Consequently, the growing frequency of rare diseases is a key factor propelling the expansion of the angioedema treatment market.

Which Segments Are Included In The Analysis Of The Angioedema Treatment Market?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Which Trends Are Impacting The Growth Of The Angioedema Treatment Market?

Leading companies within the angioedema treatment market are concentrating on creating advanced solutions, including subcutaneous injections, to provide patients experiencing acute hereditary angioedema (HAE) attacks with more convenient and quicker relief. Subcutaneous injections involve a technique where medication is administered into the fatty layer directly under the skin, facilitating its gradual and consistent absorption into the bloodstream. An illustrative example is CSL Limited, an Australia-based biotechnology company, which introduced ANDEMBRY (garadacimab) in April 2025. This product serves as a new, fully human monoclonal antibody therapy designed to prevent acute attacks in individuals with hereditary angioedema (HAE). Notably, ANDEMBRY stands as the inaugural pre-filled pen designed for once-monthly subcutaneous delivery, presenting an accessible long-term prophylactic alternative. Its mechanism involves inhibiting activated Factor XII (Factor XIIa), a crucial initiator in the biochemical sequence that results in angioedema. This marks a substantial progression in HAE management, delivering effective, patient-focused disease control.

Which Key Industry Participants Are Active In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Read the full angioedema treatment market report here:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Angioedema Treatment Market?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Angioedema Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24460&type=smp

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the angioedema treatment market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Angioedema Treatment Market?

The angioedema treatment market has seen substantial expansion in recent years. This market is set to increase from $3.13 billion in 2025 to $3.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.8%. Factors contributing to its historical growth include the necessity for emergency allergy management, prevalent hospital-based care, the use of corticosteroids, the accessibility of antihistamines, and the restricted availability of highly targeted medications.

The angioedema treatment market is projected to experience substantial growth over the coming years, reaching a valuation of $6.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.5%. This anticipated expansion throughout the forecast period stems from factors such as the advancement of biologic drugs, an increase in genetic testing, the proliferation of specialty allergy clinics, enhanced patient education, and a heightened focus on preventive care. Key trends anticipated during this period encompass a greater adoption of targeted bradykinin therapies, the expansion of hereditary angioedema treatments, the broader implementation of emergency treatment protocols, enhanced awareness in diagnostics, and a continued emphasis on preventive therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24460&type=smp

What Drivers Are Supporting Technological Adoption In The Angioedema Treatment Market?

The angioedema treatment market is projected to expand due to an increasing occurrence of rare diseases. These are defined as medical conditions impacting a very small segment of the population, often characterized by few treatment choices and substantial health effects. The rise in rare disease cases is attributed to progress in genetic testing and diagnostic technologies, which allow healthcare providers to identify and precisely diagnose conditions previously missed, thereby increasing their reported prevalence. Angioedema treatment benefits rare conditions like hereditary angioedema by offering specific therapies that help prevent and control severe swelling episodes, thus enhancing patient results. For example, in November 2024, the Food and Drug Administration, a US-based federal agency, reported that more than 7,000 rare diseases affected over 30 million individuals in the United States. Consequently, the growing incidence of rare diseases is fueling the expansion of the angioedema treatment market.

Which Segments Are Contributing To The Growth Of The Angioedema Treatment Market?

The angioedema treatment market covered in this report is segmented –

1) By Type: Allergic Angioedema, Drug-Induced Angioedema, Idiopathic Angioedema, Hereditary Angioedema

2) By Route Of Administration: Injection, Oral

3) By End Use: Hospitals, Clinics, Research Organizations

Subsegments:

1) By Allergic Angioedema: Antihistamines, Corticosteroids, Epinephrine, Immunotherapy, Allergen Avoidance Therapies

2) By Drug-Induced Angioedema: Discontinuation of Causative Drug, Antihistamines, Corticosteroids, Epinephrine, Bradykinin Pathway Inhibitors

3) By Idiopathic Angioedema: Empirical Antihistamine Therapy, Corticosteroid Therapy, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Observation and Symptom Management

4) By Hereditary Angioedema: C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Attenuated Androgens, Antifibrinolytics

Which Trends Are Guiding The Evolution Of The Angioedema Treatment Market?

Leading companies within the angioedema treatment market are dedicating efforts to developing inventive solutions, including subcutaneous injections, aiming to provide enhanced convenience and quicker alleviation for individuals experiencing acute hereditary angioedema (HAE) attacks. This method involves administering medication into the fatty tissue directly under the skin, facilitating a gradual and consistent absorption into the bloodstream. For example, in April 2025, CSL Limited, an Australia-based biotechnology company, introduced ANDEMBRY (garadacimab). This product serves as a novel, fully human monoclonal antibody treatment designed to prevent acute attacks in patients with hereditary angioedema (HAE). ANDEMBRY distinguishes itself as the inaugural pre-filled pen engineered for once-monthly subcutaneous administration, thereby presenting a practical long-term prophylactic choice. Its mechanism of action involves inhibiting activated Factor XII (Factor XIIa), a critical initiator in the biochemical cascade that results in angioedema. This represents a notable progression in HAE management, delivering effective and patient-centric control of the condition.

Who Are The Major Companies Operating In The Angioedema Treatment Market?

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/angioedema-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Angioedema Treatment Market?

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Angioedema Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24460&type=smp

Browse Through More Reports Similar to the Global Angioedema Treatment Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Retinal Vein Occlusion Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model